Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Merck Frosst Canada, Inc.

Clarence S Rooney

Edward J Cragoe, Jr

Haydn W Williams

Joshua Rokach

William F Hoffman

Ta J Lee

Joseph G Atkinson

Yves Girard

Edward L Engelhardt

Arthur A Patchett

Patrice C Belanger

David C Remy

Walfred S Saari

Robert L Smith

John S Wai

Jacob M Hoffman, Jr

Peter Kulsa

Grant W Reader

John J Baldwin

William J Greenlee

Theresa M Williams

William C Lumma, Jr

Philip E Sanderson

John D Prugh

Joel R Huff

Terrence M Ciccarone

James H Jones

Jacob M Hoffman

Susan F Britcher

Anthony M Smith

Suresh K Balani

Mark E Goldman

Burton Kendall Wasson

Norman R Hunter

Edward J Gragoe, Jr

Hayden Windsor Williams

Albert A Deana

Anthony D Theoharides, Deceased

Novel indole compounds inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Inhibitors of HIV reverse transcriptase

Novel aminopyridones inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Compounds of general formula: ##STR1## are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and related disorders such as glaucoma.

Heterobicyclic sulfonamides

Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II) ##STR1## and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.

Antihypercholesterolemic compounds

Novel HMG-CoA reductase inhibitors of formulae (I) and (II) are disclosed. ##STR1##

Novel HMG-CoA reductase inhibitors

Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.

Novel 3-hydroxy-3-methylglutary-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.

Novel HMG-CoA reductase inhibitors of formulae (I) and (II) are disclosed: ##STR1##

Novel 6H-dibenz[b,e][1,4]oxathiepin derivatives of the formulae I and Ia are employed in the treatment and control of allergic conditions such as allergic asthma. ##STR1##

6H-dibenz[b,e][1,4]oxathiepin compounds

Growing community of inventors

Worcester, PA, United States of America

Clarence S Rooney